ES2160700T3 - Derivados aromaticos de 2-amino-imidazol como agonistas del adrenorreceptor alfa-2a. - Google Patents

Derivados aromaticos de 2-amino-imidazol como agonistas del adrenorreceptor alfa-2a.

Info

Publication number
ES2160700T3
ES2160700T3 ES95910135T ES95910135T ES2160700T3 ES 2160700 T3 ES2160700 T3 ES 2160700T3 ES 95910135 T ES95910135 T ES 95910135T ES 95910135 T ES95910135 T ES 95910135T ES 2160700 T3 ES2160700 T3 ES 2160700T3
Authority
ES
Spain
Prior art keywords
sub
treatment
rent
group
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95910135T
Other languages
English (en)
Inventor
Stephen A Munk
Michael E Garst
Dale A Harcourt
Charles Gluchowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Application granted granted Critical
Publication of ES2160700T3 publication Critical patent/ES2160700T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPUESTOS DE FORMULA (I) QUE SON AGONISTAS SELECTIVOS DE {AL}{SUB,2A} Y METODOS PARA ESTIMULAR DE FORMA SELECTIVA ADRENOCEPTORES DE {AL}{SUB,2A} PARA EFECTOS TERAPEUTICOS EN UN MAMIFERO MEDIANTE LA ADMINISTRACION DE COMPUESTOS DE FORMULA (I) EN DONDE R{SUB,1} ES ALQUILO O ALQUENILO DE 1 A 4 CARBONOS, CICLOPROPILO, CL, BR, I, -OR{SUB,4}, -SR{SUB,4}, NR{SUB,4}R{SUB,4} O -SI(R{SUB,4}){SUB,3} EN DONDE R{SUB,4} REPRESENTA ALQUILO O ALQUENILO DE 1 A 4 ATOMOS DE CARBONO O ES HIDROGENO, R{SUB,2} Y R{SUB,3} SON SELECCIONADOS A PARTIR DEL GRUPO QUE CONSTA DE R{SUB,1} E HIDROGENO; O R{SUB,1} Y R{SUB,2} TOMADOS JUNTOS A PARTIR DE UN ANILLO FUNDIDO CON LA PORCION DE FENILO Y SON SELECCIONADOS A PARTIR DEL GRUPO QUE CONSTA DE (CH{SUB,2}){SUB,4}-, -NH(CH{SUB,2}){SUB,2}NH-, O(CH{SUB,2}){SUB,2}O-, -NH(CH{SUB,2}){SUB,2}O-, S(CH{SUB,2}){SUB,2}S-, -NH(CH{SUB,2})S-, Y -O(CH{SUB,2}){SUB,2}SY R{SUB,3} ES SELECCIONADO DEL GRUPO QUE CONSTA DE R{SUB,1} E HIDROGENO; O R{SUB,2} Y R{SUB,3} TOMADOS JUNTOS FORMAN UN ANILLO FUNDIDO CON LA PORCION DE FENILO Y SON SELECCIONADOS DEL GRUPO QUE CONSTA DE -(CH{SUB,2}){SUB,4}-, -NH(CH{SUB,2}){SUB,2}NH-, O(CH{SUB,2}){SUB,2}O-, -NH(CH{SUB,2}){SUB,2}O-, S(CH{SUB,2}){SUB,2}S-, -NH(CH{SUB,2})S-, Y -O(CH{SUB,2}){SUB,2}S, -CH=CH-CH=CH-, -N=CH-CH=N- Y -N=CH-N=CH-, O SALES ACEPTABLES FARMACEUTICAMENTE DE LOS MISMOS. LOS METODOS TERAPEUTICOS ENCUENTRAN SU USO EN EL TRATAMIENTO DE LAS CONDICIONES SENSIBLES AL TRATAMIENTO DE AGONISTAS DE {AL}{SUB,2A} EN TALES USOS COMO UNA REDUCCION O MANTENIMIENTO DE LA PRESION INTRAOCULAR EN AL MENOS UN OJO; EL TRATAMIENTO DE DOLOR PERIFERICO; AUMENTO DE LOS EFECTOS DE ANESTESICOS; TRATAMIENTO DE HIPERTENSION; TRATAMIENTO DE HIPERGLUCEMIA; Y SEDACION.
ES95910135T 1994-01-24 1995-01-24 Derivados aromaticos de 2-amino-imidazol como agonistas del adrenorreceptor alfa-2a. Expired - Lifetime ES2160700T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18565394A 1994-01-24 1994-01-24
US18640694A 1994-01-24 1994-01-24

Publications (1)

Publication Number Publication Date
ES2160700T3 true ES2160700T3 (es) 2001-11-16

Family

ID=26881341

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95910135T Expired - Lifetime ES2160700T3 (es) 1994-01-24 1995-01-24 Derivados aromaticos de 2-amino-imidazol como agonistas del adrenorreceptor alfa-2a.

Country Status (6)

Country Link
EP (1) EP0741709B1 (es)
JP (1) JP3805360B2 (es)
CA (1) CA2181909C (es)
DE (1) DE69521883T2 (es)
ES (1) ES2160700T3 (es)
WO (1) WO1995019968A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19514579A1 (de) 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
EP0828491A1 (en) * 1995-05-12 1998-03-18 Allergan Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects
JP3719609B2 (ja) 1995-12-21 2005-11-24 アルコン ラボラトリーズ，インコーポレイテッド 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
CA2272683A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6602897B2 (en) 2000-10-14 2003-08-05 Boehringer Ingelheim Pharma Kg m-Amino-phenylimino-imidazolidine derivatives for treating urinary incontinence
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
DE10304374A1 (de) * 2003-02-04 2004-08-05 Aventis Pharma Deutschland Gmbh Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US20050059664A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
AU2008286818B2 (en) * 2007-08-15 2014-03-27 Allergan, Inc. Adrenergic compounds
IE20070935A1 (en) * 2007-12-21 2009-06-24 Trinity College Dublin Guanidine based compounds and their use in the treatment of mental and neurological disorders.
WO2022236253A1 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459763A (en) * 1966-01-25 1969-08-05 Geigy Chem Corp Certain amino imidazole derivatives
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

Also Published As

Publication number Publication date
DE69521883T2 (de) 2002-04-04
WO1995019968A1 (en) 1995-07-27
CA2181909C (en) 2008-10-07
EP0741709B1 (en) 2001-07-25
DE69521883D1 (de) 2001-08-30
AU1835195A (en) 1995-08-08
CA2181909A1 (en) 1995-07-27
EP0741709A1 (en) 1996-11-13
AU690645B2 (en) 1998-04-30
JPH09508129A (ja) 1997-08-19
JP3805360B2 (ja) 2006-08-02

Similar Documents

Publication Publication Date Title
ES2160700T3 (es) Derivados aromaticos de 2-amino-imidazol como agonistas del adrenorreceptor alfa-2a.
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
MX9307940A (es) Nuevos derivados de la imidazopiridina, proceso para su preparacion y formulaciones farmaceuticas que los incluyen
AR035158A1 (es) Inhibidores de recaptacion de norepinefrina altamente selectivos y metodo para usar los mismos
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
PE20010740A1 (es) Aminoacidos biciclicos como agentes farmaceuticos
SV2002000197A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas ref. pc10602/20073/bb
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
AR032778A1 (es) Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
AR015448A1 (es) COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
DE68904586D1 (de) Histamin-derivat, verfahren zu dessen herstellung und therapeutischen anwendung.
MX9604687A (es) Procedimiento para la preparacion de derivados de imidazo-benzodiacepina.
ES2058596T3 (es) Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso.
AR012723A1 (es) Derivados triptolidos utiles en el tratamiento de enfermedades autoinmunes y usos en la fabricacion de medicamentos
ES2158996T3 (es) Agonistas beta3 adrenergicos selectivos.
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
AR004691A1 (es) Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion
ATE173252T1 (de) Arylmorpholine, herstellung und verwendung
KR960703912A (ko) 중추신경계 활성을 갖는 헤테로사이클 아민(heterocyclic amines having central nervous system activity)
KR900015726A (ko) 이뇨제, 소염제 및 뇌혈제관제로서의 7-치환 아미노-8-치환 카르보닐-메틸아미노-1-옥사스피로[4,5]데칸
SV2001000465A (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos ref. pc10733/20144/bb

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 741709

Country of ref document: ES